Biacore Biacore International AB has announced new data that demonstrates proof-of-principle of its surface plasmon resonance (SPR) array chip technology in relevant biological applications.
The technology, which is expected to increase the number of detailed biological evaluations in drug discovery, is being developed with pharmaceutical companies including Millennium Pharmaceuticals.
Using a prototype instrument, scientists at Millennium was able to reproducibly immobilise multiple biomarker binders and test them against multiple samples on an array platform. The experiments provided information on all of the individual binding events occurring, with no cross reactivity between samples and no background problems. In addition, the results can be used to generate kinetic information.
The results were obtained in real time, without the use of any radioactive or fluorescent labels.
Millennium Pharmaceuticals recently presented these results at the Annual Meeting of the Association of Biomolecular Resource Facilities in Austin, Texas, USA. "Through our work with Millennium, we have been able to demonstrate the feasibility of performing complex assays at higher throughput, while providing the most detailed information available on individual binding events,“ said Julian Abery, Vice President and Head of the Pharmaceutical and Biotechnology Business Unit, Biacore AB.
For more information visit www.biacore.com
